Get startedLog in
    Picture of Intelgenx Technologies logo

    IGX — Intelgenx Technologies News Story

    0.000.00%
    ca flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapMomentum Trap
    All News

    Brief: IntelGenx Receives Health Canada Clearance To Begin Phase 2a Study With Montelukast Versafilm

    Picture of Intelgenx Technologies logoIntelgenx Technologies
    15/12/2017 13:00
    Dec 15 (Reuters) - IntelGenx Technologies Corp  IGX.V : 
    * INTELGENX RECEIVES HEALTH CANADA CLEARANCE TO BEGIN PHASE 
2A 
STUDY WITH MONTELUKAST VERSAFILM(TM) IN MILD TO MODERATE 
ALZHEIMER'S DISEASE 
    * INTELGENX TECHNOLOGIES SAYS PHASE 2A PROOF OF CONCEPT 
CLINICAL 
STUDY WILL START SCREENING AD PATIENTS IN Q1 2018 
 
Source text for Eikon:  ID:nCCNdJrX1a  
Further company coverage:  IGX.V  
 
 ((bangalore.newsroom@thomsonreuters.com;))

    Recent news on Intelgenx Technologies

    See all news